In-Situ Hybridization Market Report 2026

The in-situ hybridization market size has grown strongly in recent years. It will grow from $1.78 billion in 2025 to $1.94 billion in 2026 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to expansion of molecular pathology applications, increased cancer biomarker testing, wider use of fluorescence microscopy, growth of academic genomics research, increasing adoption of ish in infectious disease studies.

The in-situ hybridization market size is expected to see strong growth in the next few years. It will grow to $2.76 billion in 2030 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to rising demand for precision oncology diagnostics, growing integration of ai-driven image analysis, expansion of personalized medicine research, increasing investments in molecular diagnostics infrastructure, development of advanced probe technologies. Major trends in the forecast period include increasing adoption of multiplex ish techniques, rising use of automated slide scanning systems, growing demand for high-resolution spatial gene expression analysis, expansion of digital pathology integration, enhanced focus on companion diagnostics.

The growing incidence of cancer is expected to drive the expansion of the in-situ hybridization market in the coming years. Cancer is a disease characterized by the uncontrolled growth of abnormal cells that can invade or spread to other parts of the body. The increase in cancer cases is largely attributed to rising life expectancy, as aging increases the likelihood of genetic mutations accumulating and prolonged exposure to cancer-causing factors. In-situ hybridization (ISH) plays an essential role in cancer management by allowing the identification of specific genetic abnormalities within tumor cells. It is widely used for precise diagnosis, prognosis, and to inform targeted therapy decisions. For example, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, new cancer cases are projected to surpass 35 million by 2050, representing a 77% increase compared with the estimated 20 million cases in 2022. Therefore, the increasing incidence of cancer is boosting the growth of the in-situ hybridization market.

Major companies operating in the in-situ hybridization market are concentrating on the development of advanced solutions, such as HER2 testing solutions, to support the prediction of patient responses to targeted therapies. HER2 testing solutions are diagnostic tools used to determine the presence and expression levels of the HER2 protein in cancer cells, guiding targeted treatment decisions. For instance, in December 2023, Cytelabs, an India-based cancer diagnostic services provider, introduced dual in-situ hybridization (DISH) testing for breast cancer patients. The US FDA-approved DISH technology marks a significant advancement in accurate HER2 testing, which is critical for targeted breast cancer therapy. It significantly reduces turnaround time by delivering HER2 status results within 24 to 48 hours, helping to alleviate stress for patients and their families. By providing reliable results quickly, DISH supports timely treatment planning and initiation. As HER2 status is vital for determining prognosis and therapy, accurate and efficient testing is essential for the appropriate evaluation of all invasive breast cancers.

In January 2025, Leica Biosystems, a Germany-based biotechnology company, partnered with Molecular Instruments to enable complete RNA-ISH workflows using the BOND RX and BOND RXm research staining systems. This collaboration integrates HCR Pro RNA-ISH with existing BOND immunohistochemistry and immunofluorescence techniques, allowing the simultaneous detection of RNA and proteins within the same tissue sample. This advancement enables researchers to obtain more comprehensive spatial information while conserving limited tissue samples. Molecular Instruments is a US-based biotechnology company.

Major companies operating in the in-situ hybridization market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Danaher Corporation, Merck KGaA, Agilent Technologies Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen NV, Bio-Techne Corporation, Leica Biosystems Nussloch GmbH, Biocare Medical LLC, BioGenex Srl, Oxford Gene Technology Inc., Creative Biolabs, Empire Genomics LLC, Abnova Corporation, BioView Ltd., Advanced Cell Diagnostics Inc., BioCat GmbH, Bio SB Inc., Genemed Biotechnologies Inc.

North America was the largest region in the in-situ hybridization market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in-situ hybridization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the in-situ hybridization market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the in-situ hybridization market by increasing costs of imported analytical instruments, fluorescence microscopes, probes, reagents, and image analysis software. Diagnostic laboratories and research institutes in North America and Europe are most affected due to reliance on imported high-precision instruments, while Asia-Pacific faces higher costs for reagent sourcing. These tariffs are elevating operational costs and slowing laboratory upgrades. However, they are also supporting regional manufacturing of reagents, localized software development, and increased investment in domestic diagnostic instrument production.

The in-situ hybridization market research report is one of a series of new reports that provides in-situ hybridization market statistics, including in-situ hybridization industry global market size, regional shares, competitors with a in-situ hybridization market share, detailed in-situ hybridization market segments, market trends and opportunities, and any further data you may need to thrive in the in-situ hybridization industry. This in-situ hybridization market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

In-situ hybridization (ISH) is a molecular technique used to detect and visualize specific DNA or RNA sequences within preserved cells or tissue sections. The method involves applying labeled complementary probes that bind to target genetic material, enabling researchers to determine the location of specific genes or transcripts while preserving tissue architecture. ISH is widely used in research and clinical settings to analyze gene expression, detect chromosomal abnormalities, identify viral infections, and support cancer diagnosis, providing detailed spatial and molecular information within biological samples.

The primary products of in-situ hybridization include analytical instruments, kits and reagents, software and services, and others. Analytical instruments are specialized systems used to detect, measure, and analyze biological, chemical, or physical characteristics within a sample. ISH employs technologies such as fluorescence in situ hybridization, chromogenic in situ hybridization, and dual-color in situ hybridization, and is applied in areas including cancer diagnosis, cytogenetics, developmental biology, infectious diseases, immunology, and others. These products are used by various end users, including hospitals and diagnostic laboratories, academic and research institutes, contract research organizations, and pharmaceutical and biotechnology companies.

The in-situ hybridization market consists of revenues earned by entities by providing services such as custom probe design, tissue sample preparation, assay development, multiplexing services, and validation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The in-situ hybridization market also includes sales of slide processing equipment, positive and negative control slides, hybridization chambers, and nuclease-free consumables. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.